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Background: Venous thromboembolism (VTE) is a major cause of mortality. 
Factor V Leiden (FVL), methylenetetrahydrofolate reductase (MTHFR) C677T, 
and prothrombin (FII) G20210A polymorphisms are the main inherited risk 
factors for VTE. Since evidence is limited on homozygotes, the aim of this study 
was to investigate the association between homozygous variants of these 
polymorphisms and VTE in Shahrekord, southwest Iran. 
Materials and Methods: In this case-control study, blood samples of 72 VTE 
patients admitted to Hajar Hospital, Shahrekord and 306 sex- and age-matched 
healthy volunteers as controls were taken in EDTA Vacutainers. The 
polymorphisms of FVL, MTHFR C677T, and FIIG20210A were investigated by 
PCR-RFLP. The data were analyzed by descriptive statistics and independent t-
test. 
Results: The frequency of all homozygous polymorphisms was found to be 
16.77% in patients and 4.90% in controls with a significant difference (P=0.004). 
Homozygous FVL mutation was more frequent in patients than in controls with 
no significant difference. Regarding the frequency of homozygous MTHFR 
C677T, a significant difference was noted between patients and controls 
(P=0.03). There was no significant difference in homozygous FIIG20210A and 
heterozygous variants of the above-mentioned polymorphisms between the 
patients and controls.  
Conclusion: Homozygous MTHFR C677T polymorphism is associated with 
VTE in Shahrekord. Control of the acquired risk factors may be necessary in 
homozygous form of this polymorphism. VTE patients with this polymorphism 
may need to be managed differently.  
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INTRODUCTION 
Venous thromboembolism is a disease in which both 
inherited and acquired factors may be involved. Although 
the real prevalence of VTE, consisting of deep venous 
thrombosis (DVT) and pulmonary embolism (PE), remains 
to be determined in many communities, it is known to be 
one of the main causes of mortality. In the United States, 
VTE is considered as the third leading cause of mortality 
and a leading cause of unpredictable deaths (1). Even the 
people who survive PE have a lower quality of life than 
healthy people (2). 
Coagulation factor deficiencies, platelets abnormalities, 
impaired vessel wall, and coagulation inhibitors can 
contribute to developing thrombosis. Thrombophilia is a 
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condition which is conducive to developing thrombosis. 
Factor V Leiden (FVL), prothrombin (FII) G20210A, and 
methyltetrahydrofolate reductase (MTHFR) C677T 
polymorphisms are the main risk factors for VTE. 
Moreover, the role of factor XIII and platelet glycoprotein 
IIb/IIIa has been recently considered in VTE (3, 4). FVL is a 
mutation of coagulation factor V that makes FVL resistant 
to protein C, its inhibitor (5). MTHFR plays an important 
role in maintaining homocysteine level. The C677T 
polymorphism of MTHFR molecule makes the enzyme 
heat resistant and may increase serum homocysteine which 
is a predisposing factor for thrombosis (6). The MTHFR 
C677T has been reported to be associated with increased 
VTE in a Chinese population but some conflicting data 
have been reported in other ethnicities (7). The FIIG20210A 
polymorphism is associated with increased plasma 
prothrombin level and increased risk of venous thrombosis 
(8), and the FIIG20210A carriers are at 2-3 times higher risk 
for developing VTE (9, 10). The frequencies of these 
polymorphisms vary depending on the racial origins in 
both normal and VTE patient populations (9-11), and the 
available data confirm widely variable distribution of 
different polymorphisms. 
 We have already found that PLA2 polymorphism of 
platelet glycoprotein IIb-IIIa is associated with increased 
risk of developing VTE and severity of PE (3, 12). Because 
homozygosity in any of the polymorphisms can increase 
the gene products and relevant data are limited, the aim of 
this study was to investigate the association between 
homozygous variants of these mutations and VTE. 
   
MATERIALS AND METHODS 
Patients 
In this study, 72 patients with VTE who were admitted 
to Hajar Hospital, Shahrekord, Iran and presented with 
one or more symptoms of PE or DVT at the time of 
diagnosis were enrolled. The control group consisted of 
306 sex and age-matched healthy individuals without 
history of venous or arterial diseases living in the same 
region. Both patients and healthy controls provided 
informed consent to participate in the study before blood 
sample collection. The ethical approval for the study was 
obtained from the Shahrekord University of Medical 
Sciences Ethics Committee (Code; 638). 
Detection of polymorphisms  
All the patients and controls were investigated for FVL, 
MTHFR and FIIG20210A polymorphisms. Blood samples 
were taken from the participants in EDTA Vacutainers and 
transferred to the Cellular and Molecular Research Center 
of the Shahrekord University of Medical Sciences. DNA 
was extracted from total blood by phenyl-chloroform 
extraction, quantitated by a spectrophotometer (Unico 
2010), and then standardized. The polymorphisms of 
interests were investigated by PCR-RFLP. A DNA-free 
solution was used as negative control.  
The genes of interest were amplified by a thermocycler 
(ASTEC, PC818, Japan). The primers which were used to 
investigate each mutation were designed according to 
Ivanov et al. study (13), and are listed in Table 1. The 
restriction enzymes consisted of Mn1l for FVL, Hinf1 for 
MTHFR C677T, and Hindlll for FIIG20210A. The restriction 
enzymes were provided by Tags (Copenhagen, Denmark) 
and the primers were purchased from Fermentase (Russia). 
An 8% polyacrylamide gel was used to investigate the final 
products and the bands were observed by Coomassie 
Brilliant Blue staining.  
 
Table 1. Primer sequences of genetic polymorphisms 
 
Genetic polymorphisms Primers 
FVL F 5′ TGC CCA GTG CTT AAC AAG ACC A 3′ 
R 5′ TGT TAT CAC ACT GGT GCT AA 3′ 
MTHFR C677T F 5′ TGA AGG AGA AGG TGT CTG CGG GA 3′ 
R 5′ AGG ACG GTG CGG TGA GAG TG 3′ 
FIIG20210A F 5′ TCT AGA AAC AGT TGC CTG GC 3′ 
R 5′ ATA GCA CTG GGA GCA TTG AAG C 3′ 
 
The thermal cycling programs of the studied 
polymorphisms were as follows:  
FVL mutation: Four minutes at 96°C, six cycles of 60 
seconds at 96°C, 60 seconds at 58°C, and 60 seconds at 
72°C, followed by 28 cycles of 30 seconds at 96°C, 30 
seconds at 56°C, and 30 seconds at 72°C, and a final 
extension of 5 minutes at 72°C. 
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MTHFR C677T polymorphism: Five minutes at 94°C 
followed by five cycles of 60 seconds at 94°C, 60 seconds at 
59°C, and 60 seconds at 72°C, and then 25 cycles of 30 
seconds at 94°C, 30 seconds at 59°C, and 30 seconds at 
72°C, and a final extension of 10 minutes at 72°C. 
FIIG20210A polymorphism: Five minutes at 94°C 
followed by 33 cycles of 30 seconds at 94°C, 45 seconds at 
60°C, and 60 seconds at 72°C, and a final extension of 5 
minutes at 72°C. 
A 267-bp fragment was amplified from FVL by the 
primers required to identify G1691A mutation. In the un-
mutated allele, two cleavage sites of the Mn1l enzyme are 
present and therefore three fragments of 163, 67, and 37 bp 
are developed. If the mutation of interest exists, an enzyme 
site is deleted via G --> A at the point 1691 of the relevant 
gene and two fragments of 200 and 67 bp are developed. 
Using the primers required to identify the MTHFR 
C677T polymorphism, a 198-bp fragment was amplified. In 
the un-mutated allele, there is no cleavage site of Hinfl 
enzyme and therefore the 198-bp fragment remains. If the 
mutation of interest exists, an enzyme site is developed in 
the 198-bp fragment through C --> T at the point 677 of the 
relevant gene and two fragments of 175 and 23 bp are 
developed. 
To detect the FIIG20210A polymorphism, a 345-bp 
fragment was amplified. The wild variant of this 
polymorphism has no cleavage site of HindIII enzyme. If 
the FIIG20210A polymorphism is present, a cleavage site is 
created for the enzyme and two fragments of 322 and 23 bp 
are developed. 
Statistical analysis 
The data were analyzed by SPSS 18. Descriptive 
statistics were used for the demographic characteristics. 
The significance of the differences in the distribution of 
homozygous polymorphisms between the patients and the 
controls was investigated by chi-square test, and P<0.05 
was considered significant. Moreover, the odds ratio (OR) 
was used to represent the association of the 
polymorphisms with VTE. 
RESULTS 
Demographic characteristics of patients 
Thirty-seven patients had PE and the remaining had 
DVT. The mean age of the patients was 42.12±18.59 years; 
40.27% of the patients were males. The mean age of male 
patients was lower than that of female patients with no 
significant difference (P>0.05). There was no significant 
difference in the age of patients with homozygous and 
heterozygous mutations.  
Homozygous and heterozygous polymorphisms in 
patients 
Out of 72 studied patients, 16.66% and out of controls, 
4.90% had homozygous mutations of the studied 
polymorphisms (P=0.004, Table 2). FVL was seen in four 
(5.55%) patients, MTHFR C677T in 32 (44.14%), and 
FIIG20210A in one (1.4%) patient. Table 3 compares the 
frequency of heterozygous and homozygous 
polymorphisms between the patients and controls. Figure 
1 illustrates the PCR-RFLP products of FVL, MTHFR 
C677T, and FIIG20210A on polyacrylamide gel. 
 
Table 2. Comparison of homozygous thrombophilia polymorphisms between VTE 
patients and controls 
 
 Frequency Percentage 
Mean polymorphism/ 
individual 
P-
value 
Patients (72) 12 16.66 0.2 0.004 
Controls (306) 15 4.90 0.04  
 
Homozygous FVL mutation had a frequency of 2.77% 
in the patients and 0.32% in the controls with no significant 
difference (P=0.09); 11.11% of the patients vs. 3.92% of the 
controls were homozygous for MTHFR C677T (OR=3.06, 
95% CI: 1.32-7.48). No significant difference was noted in 
the heterozygous MTHFR C677T between the patients and 
the controls (P>0.05). No patients or controls were seen to 
be homozygous for FIIG20210A polymorphism. The 
frequencies of heterozygous MTHFR C677T and 
FIIG20210A polymorphisms were not significantly 
different between the patients and the controls (Table 3). 
In two patients, one PE and one DVT, (and none of the 
controls) double homozygous FVL and MTHFR C677T was 
seen. No cases of triple homozygosity were found in the 
patients or the controls. 
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Figure 1. PCR-RFLP products of investigated polymorphisms on 8% polyacrylamide gel. 
A) FVL polymorphism: 1 indicates DNA marker, 4 homozygous FVL mutation, 3 & 5 heterozygous and 6 & 7 wild type. 
B) MTHFR C677T polymorphism: 1 indicates DNA marker, 6 homozygous mutation, 4 & 7 heterozygous and 3 & 5 wild type. 
C) FIIG20210A: 1 indicates DNA marker, 4 heterozygous and other bands wild type. 
 
 
 
Table 3. Comparison of homozygous and heterozygous thrombophilia polymorphisms between VTE patients and controls   
 
 Heterozygote polymorphisms  Homozygote polymorphisms 
Polymorphisms Patients  Controls  Patients  Controls 
FVL number (%) 2 (2.77)  6 (1.95)  2 (2.77)  1 (0.33) 
OR (95% confidence interval)  1.42(0.28-0.23)    8.7 (0.78-7.46)  
P value  NS*    0.09  
        
MTHFRC677T number (%) 24 (33.33)  98(32.03)  8 (11.11)  12 (3.92) 
OR (95% confidence interval)  1.06 (0.62-1.83)    3.06 (1.23-0.84)  
P value  NS    0.03  
        
FIIG20210A Number (%) 1 (1.4)  3 (1)  0  0 
OR (95% confidence interval)  1.42 (0.146-13.88)    -  
P value  NS    -  
FVL: Factor V Leiden, MTHFRC677T: Polymorphism C677T in methylenetetrahydrofolate reductase, FII: Prothrombin 
NS: Not significant 
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DISCUSSION 
This study demonstrated that VTE was associated with 
a number of homozygous thrombophilic polymorphisms, 
and some of the known thrombophilic homozygous 
polymorphisms increased the risk of developing VTE, 
while others had no effect. In a study on factor XIII 
polymorphisms, homozygous FXIIIA-V34L was found to 
protect against VTE, while heterozygous FXIIIA-V34L and 
XIIIB-H95R had no effect (4). Besides, the frequency of 
coincidence of thrombophilic mutations was found to be 
higher in DVT patients than in PE patients and controls 
(14). In a study conducted in an Australian Caucasian 
population, 64.2% and 24.5% of studied group were 
homozygous and heterozygous, respectively at least for 
one of the inherited thrombophilia; these values are higher 
than our findings (15). Among the patients in our study, 
the most frequent homozygous polymorphism was found 
to be MTHFR C677T (11.11%). This polymorphism is 
distributed among all populations and is more frequent in 
some racial populations (9, 10). It has been found more 
commonly in Australians, Europeans and Chinese than 
African-Americans (15-17). Gohil et al. reported a 
significant association between MTHFR C677T and DVT in 
Chinese/Thai population but not in Caucasians (9).      
The frequency of homozygous MTHFR C677T was 
3.9% in the controls in our study, which was relatively 
lower than the values reported from Europe and Australia 
(15, 18). The significantly higher frequency of homozygous 
MTHFR C677T in patients than controls in our study is 
inconsistent with the results of Ivanov et al, reporting a 
higher frequency in the control group (13). In carriers of 
heterozygous mutation, enzyme function is about 65% of 
its normal level, whereas, this rate is only 30% in 
homozygous mutation (6). The presence of this 
polymorphism causes an increase in plasma homocysteine 
level that can contribute to the pathogenesis of arterial and 
venous thrombosis (19, 20). Kokturk et al. reported 
increased plasma homocysteine levels in patients, such that 
the risk of developing VTE increased by 4.8 times (20). In 
their study, the prevalence of homocysteinemia in VTE 
was 63% and higher in PE patients compared to DVT. 
Moreover, increased homocysteine can be due to systemic 
or endothelial oxidative stress which leads to platelet 
activation (21). 
Homozygous FVL was more frequent in patients than 
in controls (2.77% vs. 0.32%) in our study, yet with no 
significant difference. Different studies have investigated 
the contribution of FVL mutation to VTE and reported 
various frequencies of this mutation in different 
populations (9, 22, 23). Coppola et al. found homozygous 
FVL to be associated with a higher risk of thrombosis while 
heterozygous FVL was associated with a lower risk of 
thrombosis (24). In a study in Turkey, homozygous FVL 
was significantly associated with thrombosis; whereas, 
MTHFR C677T was equally distributed in patients and 
controls (25), but in a Chinese population, FVL mutation 
was not associated with VTE, which is in agreement with 
our findings (9). The inconsistent findings of different 
studies can be explained by the racial origins and also the 
environmental risk factors influencing the whole 
population of a community, including people without 
these polymorphisms, and making them predisposed to 
thrombosis.  
FIIG20210A mutation was not associated with VTE in 
our study which is consistent with the results of Bezgin et 
al, who found similar frequencies of this mutation in 
patients with different manifestations of VTE and controls 
(26). Some studies have reported the association of 
FIIG20210A mutation with VTE pathogenesis (8), while 
some others have found such associations in Caucasians 
but not in Chinese/Thai or African American populations 
(9). The latter is in agreement with our study. 
Coinheritance of thrombophilic factors can reduce the 
predisposition to bleeding in hemophilia patients (27) but 
increase the risk of thrombosis in VTE patients (3). We had 
two patients but no controls with coinheritance of 
homozygous FVL and MTHFR C677T in this study. 
Because of the limited number of patients in our study, we 
could not investigate the significance of such coinheritance. 
We studied a limited number of homozygous 
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thrombophilia polymorphisms, but some other 
polymorphisms may also be involved in VTE, which can 
be investigated in future studies.  
 
CONCLUSION 
This study demonstrated that 16.6% of VTE patients 
versus 4.90% of controls had thrombophilia homozygous 
polymorphisms and the homozygous MTHFR C677T 
polymorphism was associated with increased risk of 
developing thrombosis in patients with VTE in 
Shahrekord. These patients may need to be managed 
differently. Knowledge about the presence of these risk 
factors can help to prevent these diseases, especially 
among patients' relatives who are carriers of these 
polymorphisms, and control the acquired risk factors.  
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